Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02911467 · ClinicalTrials.gov registry record · Phase 1
Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Rahul Aggarwal.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02911467 is a Phase 1 study that was terminated before completion, run by Rahul Aggarwal. The registered enrollment target is 8 participants.
The verdict
NCT02911467, a Phase 1 study, was terminated before completion, sponsored by Rahul Aggarwal.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging with Hyperpolarized Pyruvate (HP) (13C) as a predictive response biomarker to androgen signaling inhibition in patients with castration-resistant prostate cancer.
Interventions
- DEVICE MRI
- DRUG Pyruvate (13C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-11-08 |
| Est. Completion | 2020-07-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02911467
The ClinicalTrials.gov registry entry for NCT02911467 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rahul Aggarwal, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MRI is the first listed.
NCT02911467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02911467 about?
NCT02911467 is a clinical study titled "Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer". This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging with Hyperpolarized Pyruvate (HP) (13C) as a predictive response biomarker to androgen signaling inhibition in patients with castration-resistant prostate cancer.
What is the current status of trial NCT02911467?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-11-08. Estimated completion is 2020-07-20.
What interventions are being tested in trial NCT02911467?
The interventions under investigation include: MRI (DEVICE), Pyruvate (13C) (DRUG).
Who is sponsoring clinical trial NCT02911467?
This trial is sponsored by Rahul Aggarwal, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.